GlassScriptPhysician profile
Jaqueline M Benner
NPI 1730376229
$4,682.16
in general payments reported to CMS, 2019-2025
26 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $431 · 2022: $560 · 2023: $660 · 2024: $1,215 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.00 |
| Education | $165.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $935.78 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $516.47 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $484.40 | 2021-2025 | Dupixent |
| Incyte Corporation | $369.91 | 2021-2025 | Opzelura |
| Abbvie INC. | $355.16 | 2021-2025 | |
| Lilly USA, LLC | $288.54 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $281.48 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $266.12 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $231.61 | 2021-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $174.35 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $154.99 | 2022-2025 | |
| Journey Medical Corporation | $138.03 | 2022-2024 | |
| Amgen INC. | $85.11 | 2025 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.61 | 2021-2024 | Cabtreo, Arazlo |
| Leo Pharma INC. | $56.64 | 2022-2025 | Anzupgo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $43.29 | 2025 | |
| Almirall LLC | $37.39 | 2023 | Seysara |
| Genentech USA, INC. | $30.99 | 2024 | Erivedge |
| Allergan, INC. | $28.15 | 2022 | |
| Fresenius Kabi USA, LLC | $26.50 | 2023 | Idacio |
| Kyowa Kirin, INC. | $20.76 | 2022 | |
| Biofrontera INC. | $20.25 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $19.75 | 2025 | Sofdra |
| Merz North America, INC. | $18.88 | 2021 | |
| Lnhc, INC | $14.89 | 2025 | Zelsuvmi |
| Arcutis Biotherapeutics, INC. | $14.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaqueline Benner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.